Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2/Signature 1
From BugSigDB
Reviewed Marked as Reviewed by Folakunmi on 2024-2-15
Source: Figure 2C
Description: Comparsion of patients with partial progressive survival free more than 3 months and less than 3 in fecal samples of patients (excluding those treated with antibiotics) with non-small cell lung cell lung carcinoma (NSCLC) or renal cell carcinoma (RCC) reponse at 3 months of PD-1 monoclonal antibodies (mAB) treatment
Abundance in Group 1: increased abundance in Progressive -Free- Survival more than 30 days
